Project Grant R01NS136806

Award Date 7/1/24
Completion Date 6/30/29
Dollars Obligated $2M
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This Project Grant award of $654,367 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research to investigate the neural mechanisms underlying fatigue in individuals with post-acute sequelae of SARS-CoV-2 (PASC), also known as "long COVID." The primary objectives are to: 1) determine the relationship between blood-brain barrier permeability...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $634,622 to investigate the mechanisms by which SARS-CoV-2 infection causes neurological post-acute sequelae, known as "NeuroPASC." The key products and services to be delivered include: 1) Acquiring high-resolution, multi-contrast, quantitative ex vivo MRI and detailed...
This Project Grant award of $390,178 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to identify molecular, cellular, and electrical biomarkers for diagnosing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The key product will be a matrix of biomarkers derived from investigating gene expression, functional pathways, and...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $797,157 to Yale University to conduct research aimed at understanding circuit dysfunction in individuals with neuropsychiatric manifestations of post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC). The 5-year project, starting on December 1, 2024, will leverage Yale's Neurocovid Clinic and the COVID Mind Study to recruit...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $633,045 to the University of Pittsburgh to investigate the pathogenic mechanisms and therapeutic approaches for exercise intolerance in patients with Post-Acute Sequelae of COVID-19 (PASC). The key objectives are to: 1) Evaluate the predictive value of plasma angiotensin-converting enzyme 2 (ACE2) activity as a biomarker for exercise capacity in PASC patients...
The National Institute on Aging (NIA) awarded a 3-year, $2,561,480 Project Grant (CFDA 93.866) to Brigham & Women's Hospital to study the post-acute sequelae of SARS-CoV-2 infection (PASC) and subsequent disease progression in individuals with mild cognitive impairment (MCI) or Alzheimer's disease (AD) and related dementias (ADRD). The project aims to: 1) understand the epidemiology of PASC in cognitively impaired individuals; 2) examine the impacts of COVID-19 and PASC on disease...
The National Institutes of Health's Office of the Director awarded a $8,661,331 project grant under the Lung Diseases Research program (CFDA 93.838) to the Massachusetts General Hospital on June 10, 2021 for the development of interactive data portals and analytic tools to support Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) cohorts. Key products and services delivered through Massachusetts General Hospital and several sub-awardees include an interactive data portal called the...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), is funding the development and piloting of a novel intervention to treat post-COVID cognitive impairment (CI) and depression in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). The $194,157 award will support the following key activities: 1) Developing a manualized intervention by adapting and enhancing a cognitive rehabilitation and...
This Project Grant award of $432,431.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award will support research at San Jose State University Research Foundation to investigate the use of red blood cell deformability as a potential biomarker for differentiating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients from healthy individuals. The research will utilize a high-throughput microfluidic...
The Department of the Army Medical Command awarded a $2.5 million Project Grant to Stanford University to support research exploring the role of manganese and manganese-dependent metabolic pathways in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) from June 2022 through May 2025. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research with the goals of transforming military...

CEREBRAL ENERGY METABOLISM IN ME/CFS WITH AND WITHOUT PASC - PROJECT SUMMARY MANY PATIENTS WHO HAVE RECOVERED FROM SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, CONTINUE TO EXPERIENCE A CONSTELLATION OF SYMPTOMS LONG AFTER THE INITIAL ILLNESS. KNOWN AS "LONG-COVID", OR POST- ACUTE SEQUELAE OF SARS-COV-2 INFECTION (PASC), THE MOST FREQUENTLY REPORTED SYMPTOMS ARE FATIGUE, POST EXERTIONAL MALAISE AND COGNITIVE DYSFUNCTION, WHICH ARE ALSO THE PRIMARY SYMPTOMS OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS). MANY OF THE PASC PATIENTS FULFILL DIAGNOSTIC CRITERIA FOR ME/CFS, BUT DIFFER FROM NON-PASC ME/CFS PATIENTS IN THAT THEY SHARE A COMMON INFECTIOUS TRIGGER AND HAVE A SHORTER DURATION OF ILLNESS, WHICH REDUCES HETEROGENEITY. UNDERSTANDING WHETHER PASC ME/CFS SHARES OVERLAPPING MECHANISMS WITH NON-PASC ME/CFS IS CRITICAL, AS THIS COULD PROVIDE INSIGHTS INTO THE MECHANISMS AND INFORM TREATMENT STRATEGIES OF ME/CFS IN GENERAL. TO ADDRESS THIS QUESTION, WE PROPOSE A COMPARISON STUDY OF PASC ME/CFS PATIENTS WITH SUDDEN ONSET ILLNESS TO NON-PASC ME/CFS PATIENTS WHO REPORTED A SUDDEN FLU-LIKE ILLNESS ONSET. LIMITED STUDIES HAVE SHOWN REDUCTIONS IN CEREBRAL BLOOD FLOW AND INCREASED CEREBROVENTRICULAR LACTATE IN ME/CFS PATIENTS SUGGESTING ALTERATIONS IN PERFUSION AND METABOLIC PROPERTIES. OUR RECENT PRELIMINARY RESULTS SHOW THAT THE OXYGEN EXTRACTION FRACTION WAS ELEVATED IN PASC ME/CFS PATIENTS, WHICH MAY BE ATTRIBUTED TO REDUCED CEREBRAL BLOOD FLOW AND MITOCHONDRIAL DYSFUNCTION. IN THIS PROJECT, WE AIM TO CONDUCT NON- INVASIVE BRAIN MAGNETIC RESONANCE IMAGING (MRI) TO COMPARE THE SIMILARITIES AND DIFFERENCES IN CEREBRAL OXYGEN AND GLUCOSE METABOLISM BETWEEN THE TWO PATIENT GROUPS AS WELL AS HEALTHY CONTROLS. WE WILL MEASURE AND COMPARE THE OXYGEN EXTRACTION FRACTION, CEREBRAL BLOOD FLOW, AND CEREBRAL METABOLIC RATE OF OXYGEN AND GLUCOSE UPTAKE AND METABOLIC RATE IN THE PATIENT GROUPS AND HEALTHY CONTROLS. THE MRI DERIVED PARAMETERS WILL THEN BE CORRELATED TO THE DISEASE SYMPTOM BURDEN. ADDITIONAL, SINCE MANY PASC PATIENTS RECOVER OVER ONE YEAR, WE AIM TO PERFORM A FOLLOW-UP STUDY ON THE PASC AND NON-PASC ME/CFS GROUPS. COMPLETION OF THIS TIMELY AND IMPORTANT STUDY WILL PROVIDE COMPARISON OF PASC AND NON-PASC ME/CSF IN TERMS OF CHANGES IN GLUCOSE AND OXYGEN METABOLIC PROPERTIES, AS WELL AS HOW THESE IMAGING PARAMETERS ARE RELATED TO THE DISEASE BURDEN. THROUGH ANALYSIS OF THE LONGITUDINAL DATA, WE WILL BE ABLE TO DETERMINE WHETHER THE CHANGES IN METABOLIC PROPERTIES ARE ASSOCIATED WITH CHANGES OF PATIENT REPORTED OUTCOME MEASURES. THE KNOWLEDGE LEARNED WILL DEEPEN OUR UNDERSTANDING OF THE ME/CFS/PASC (LONG-COVID) DISEASE MECHANISMS, AID IN ME/CFS DIAGNOSIS, INFORM TREATMENT DECISIONS, AND INSPIRE NEW TREATMENT TARGETS.

Posted 6/27/24, 12:00 AM